AARTIPHARM / Q4-FY26 / risks

Keep the risk register visible.

Aarti Pharmalabs · Material risks, their source context, and severity in the latest available quarter.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

WatchQ4-FY26 · 2026-04-??Back to quarter ↗

Risk intelligence

Material risks this quarter

Raw material cost inflation from West Asia tensions

Geopolitical tensions have caused significant increases in raw material and logistics costs, impacting margins, especially in the API segment where cost pass-through is difficult.

high

Inability to pass on cost increases in API/intermediates

Management noted that existing orders in the API segment cannot be repriced, and future price increases depend on competitive dynamics.

medium

Lumpy CDMO revenue and working capital strain

CDMO revenue is lumpy due to project-based deliveries, and large customer orders require significant inventory financing without advances.

medium

Forex volatility impact on profitability

A ₹33 crore forex loss in FY26 (including on foreign currency loans) highlights exposure to currency fluctuations, with potential for further hits.

medium